Observational studyThoracic cancer2024

The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study.

Hongxin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.